Millennium Management
ABUS icon

Millennium Management’s Arbutus Biopharma ABUS Stock Holding History

Millennium Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-150,000
Closed -$644K – 6697
2021
Q3 		$644K Buy
+150,000
New +$500K ﹤0.01% 5109

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Millennium Management's ABUS Position: Q1 2026 in Review

Millennium Management opened a new position in Arbutus Biopharma (ABUS) in Q1 2026: 642,448 shares worth $2.89M. The stake represents ﹤0.01% of the portfolio and ranks #3506 among its holdings. This is a return to the name: Millennium Management previously reported a position in ABUS as recently as Q3 2025.

Millennium Management first reported a position in ABUS in Q1 2014 and has held it in 42 quarters since. The position peaked at $16.2M in Q2 2015. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Millennium Management held 642,448 shares of Arbutus Biopharma worth $2.89M as of Q1 2026.
  • Arbutus Biopharma was a new Millennium Management position in Q1 2026.
  • Arbutus Biopharma made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3506 holding.
  • Millennium Management first reported a position in Arbutus Biopharma in Q1 2014 and has held it in 42 quarters since.
  • Millennium Management's Arbutus Biopharma position peaked at $16.2M in Q2 2015.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.